Lipoproteins, stroke and statins

Current Vascular Pharmacology

Volumn 13, Issue 2, 2015, Pages 202-208

  Pisciotta, Livia ^a   Bertolini, Stefano ^a   Pende, Aldo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Cardiovascular risk; Dyslipidemias; Lipid lowering therapy; Lipoproteins; Statins; Stroke

Indexed keywords

APOLIPOPROTEIN A5; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN D; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; ROSUVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ARTERIAL WALL THICKNESS; ARTERY EMBOLISM; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL OCCLUSION; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; GENETIC POLYMORPHISM; HUMAN; HYPERCHOLESTEROLEMIA; INTRACRANIAL ANEURYSM; META ANALYSIS (TOPIC); PROTEIN EXPRESSION; SUBARACHNOID HEMORRHAGE; VASCULAR AMYLOIDOSIS; VENOUS THROMBOEMBOLISM; ANIMAL; BLOOD; COMPLICATION; DYSLIPIDEMIAS; RISK ASSESSMENT; RISK FACTOR; STROKE; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84929759904     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113116660166     Document Type: Article

References (65)

1. Prospective studies collaboration, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007; 370: 1829-39
2. Emerging risk factor collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000
3. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511
4. Mahley RW, Innerarity TL, Rall SC Jr., Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984; 25: 1277-94
5. Braunwald E, Zipes DP, Libby P. Heart disease, 6th italian edition, Excerpta Medica Italia Srl: Milan 2003, p. 1061
6. Kumpula LS, Kumpula JM, Taskinen MR, Jauhiainen M, Kaski K, Ala Korpela M. Reconsideration of hydrophobic lipid distribution in lipoprotein particles. Chem Phys Lipids 2008; 155: 57-62
7. Manzato E, Zambon S, Marin R, Baggio G, Crepaldi G. Modifications of plasma lipoproteins after lipase activation in patients with chylomicronemia. J Lipid Res 1986; 27: 1248-58
8. Stein Y, Stein O. Lipoprotein lipase and atherosclerosis. Atherosclerosis 2003; 170: 1-9
9. Leaf DA. Chylomicronemia and the chylomicronemia syndrome: a practical approach to management. Am J Med 2008; 121: 10-2
10. Mason TM. The role of factors that regulate the synthesis and secretion of very-low-density lipoprotein by hepatocytes. Crit Rev Clin Lab Sc 1998; 35: 461-87
11. Ohashi R, Mu H, Wang X, Yao Q, Chen C. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM 2005; 98: 845-56
12. Ginsberg HN. Lipoprotein physiology. Endocrinol Metab Clin North Am 1998; 27: 303-19
13. Hevonoja T, Markku O, Pentikainen MT, Kovanen PT, Ala Korpela M. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim Biophys Acta 2000; 1488: 189-210
14. Hirayama S, Miida T. Small dense LDL: an emerging risk factor for cardiovascular disease. Clin Chim Acta 201; 414: 215-24
15. Barter P. HDL-C: role as a risk modifier. Atherosclerosis (Suppl) 2011; 12: 267-70
16. De Goma EM, De Goma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels: evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008; 51: 46-8
17. Shah PK, Kaul S, Nilsson J, Cerceck B. Exploiting the vascular protective effects oh high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001; 104: 2376-83
18. Undas A, Cie_la-Dul M, Dr__kiewicz T, Sadowski J. Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform. Thromb Res 2012; 130: e184-7
19. Clarke R, Peden JF, Hopewell JC, et al.Genetic variants associated with Lp(a) lipoprotein level and coronary artery disease. N Engl J Med 2009; 361: 2518-28
20. Adams HPJr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41
21. Feigin VL, Lawes CMM, Bennet DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence and case fatality in the late 20th century. Lancet Neurol 2003; 2: 43-53
22. Petty GW, Brown RDJ, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke 1999; 30: 2513-16
23. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62: 569-73
24. Sarti C, Rastenyte D, Cepaitis Z, Tuomilehto J. International trends in mortality from stroke, 1968 to 1994. Stroke 2000; 31: 1588-601
25. Vernino S, Brown RD, Sejvar JJ, Sicks JD, Petty GW, O’Fallon WM. Cause-specific mortality after first cerebral infarction. Stroke 2003; 34: 1828-32
26. Pendlebury ST, Rothwell PM. Risk of recurrent stroke, other vascular events and dementia after transient ischaemic attack and stroke. Cerebrovasc Dis 2009; 27(Suppl 3): 1-11
27. Bravata DM, Ho SY, Brass LM, Cocato J, Scinto J, Meehan TP. Long-term mortality in cerebrovascular disease. Stroke 2003; 34: 699-704
28. Khatibzadeh M, Sheikhzadeh A, Gromoll B, Stierle U. Topographic pattern of advanced atherosclerotic lesions in carotid arteries. Cardiology 1998; 89: 235-40
29. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000; 31: 1062-8
30. Caceres JA, Goldstein JN. Intracranial hemorrhage. Emerg Med Clin North Am 2012; 30: 771-94
31. Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 1998; 82(9A): 3Q-12Q
32. Parish S, Offer A, Clarke R, et al.Lipids and lipoproteins and risk of different vascular events in the MRC/BHF heart protection study. Circulation 2012; 125: 2469-78
33. Mahajan N, Ference BA, Arora N, et al.Role of non-high density lipoprotein cholesterol in predicting cerebrovascular events in patients following myocardial infarction. Am J Cardiol 2012; 109: 1694-9
34. Berger JS, Mc Ginn AP, Howard BV, et al.Lipid and lipoprotein biomarkers and the risk of ischemic stroke in postmenopausal women. Stroke 2012; 43: 958-66
35. Kim SJ, Park YG, Kim JH, Han YK, Cho HK, Bang OY. Plasma fasting and nonfasting triglycerides and high density lipoprotein cholesterol in atherosclerotic stroke: different profiles according tpo low-density lipoprotein cholesterol. Atherosclerosis 2012; 223: 463-7
36. Munshi A, Sai Babu M, Kaul S, Rajeshwar K, Balakrishna N, Jyothy A. Association of LPL gene variant and LDL, HDL, VLDL choelesterol and triglyceride levels with ischemic stroke and its subtypes. J Neurol Sci 2012; 318: 51-4
37. Kim JY, Park JH, Jeong SW, et al.High levels of remnant lipoprotein cholesterol is a risk factor for large artery atherosclerotic stroke. J Clin Neurol 2011;7:203-9
38. Nardi K, Engelter S, Strbian D, et al.Lipid profiles and outcome in patients treated by intravenous thrombolysis for cerebral ischemia. Neurology 2012; 79: 1101-8
39. Mahmood A, Sharif MA, Khan MN, Ali UZ. Comparison of serum lipid profile in ischaemic and haemorrhagic stroke. J Coll Physicians Surg Pak 2010; 20: 317-20
40. Hopewell JC, Clarke R, Parish S, et al.Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study. Circ Cardiovasc Genet 2011; 4: 68-73
41. Paternoster L, Martinez-Gonzalez NA, Charleton R, Chung M, Lewis S, Sudlow CL. Genetic effects on carotid intima-media thickness: systematic assessment and meta-analyses of candidate gene polymorphisms studied in more than 5000 subjects. Circ Cardiovasc Genet 2010; 3: 15-21
42. Paternoster L, Martínez González NA, Lewis S, Sudlow C. Association between apolipoprotein E genotype and carotid intimamedia thickness may suggest a specific effect on large artery atherothrombotic stroke. Stroke 2008; 39: 48-54
43. Yamada M. Cerebral amyloid angiopathy and gene polymorphisms. J Neurol Sci 2004; 226: 41-4
44. Prenkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 1996; 148: 2083-95
45. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498–511
46. Jones PH, Davidson MH, Stein EA, et al.Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial). Am J Cardiol 2003; 92: 152-60
47. Hunninghake JD, Stein EA, Bays HE, et al.Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron Artery Dis 2004; 15: 115-23
48. Teramoto T. The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C. Expert Opin Pharmacother 2012; 13: 859-65
49. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 2010; 55: 1283-99
50. Barter P, Gotto AM, LaRosa JC, et al.Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-10
51. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 2008; 196: 489-96
52. Amarenco P, Goldstein LB, Callahan A 3rd, et al.Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Atherosclerosis 2009; 204: 515–20
53. De Caterina R, Scarano M, Marfisi R, et al.Cholesterol-lowering interventions and stroke. Insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2010; 55: 198-211
54. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96(5A): 24F-33F
55. Li H, Förstermann U. Prevention of atherosclerosis by interference with the vascular nitric oxide system. Curr Pharm Des 2009; 15: 3133-45
56. Libby P, Aikawa M. Mechanism of plaque stabilization with statins. Am J Cardiol 2003; 91(4A): 4B-8B
57. Pearson TA, Mensah GA, Alexander RW, et al.Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003; 107: 499-511
58. Glynn RJ, Danielson E, Fonesca FA, et al.A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Eng J Med 2009; 360: 1851-61
59. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009; 203: 325-30
60. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral haemorrhage. A meta-analysis of 31 randomized controlled trials. Stroke 2012; 43: 2149-56
61. Rocco A, Sykora M, Ringleb P, Diedler J. Impact of statin use and lipid profile on symptomatic intracerebral haemorrhage, outcome and mortality after intravenous thrombolysis in acute stroke. Cerebrovasc Dis 2012; 33: 362-8
62. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDLcholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 2008; 14(8 Suppl): S3-28
63. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad Med J 2008; 84: 590-8
64. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010; 31: 149-64
65. Kuo F, Gardener H, Dong C, et al.Traditional cardiovascular risk factors explain the minority of the variability in carotid plaque. Stroke 2012; 43: 1755-60.